Current Portfolio
XyloCor Therapeutics
US biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease.
Key Facts
- Sector
Life Sciences
- Country
United States
- Fund
LSP 6
- Entry
2018
Website
Do You Want to Know More?
We are eager to explore how we can achieve great things together.